Empowering Ethiopia: Horizon Europe Grants €4M to Tackle Non-Communicable Diseases

By HEOR Staff Writer

August 17, 2023

The ENABLE research consortium has been awarded a generous €4 million grant from Horizon Europe to combat non-communicable diseases (NCDs) in Ethiopia.

The ENABLE consortium, a collaboration between the Norwegian Institute of Public Health (NIPH) and the Ethiopian Public Health Institute (EPHI), will kick off its mission in 2024 for a period of 4 years.

The project aims to establish a program, using evidence-based interventions, to promote healthy eating habits, increase physical activity, and reduce exposure to pollution within urban communities in Ethiopia.

This initiative will be delivered across four Ethiopian cities: Addis Ababa, Adama, Harar, and Jimma, targeting pregnant women and their children in particular.

This is a prime example of how combining public health, healthcare access, and environmental health, supported by digital tools, can significantly improve a population’s health.

This project aligns with Ethiopia’s National NCD prevention strategy and contributes to closing the global knowledge gap for implementing evidence-based interventions.

The team is led by Dr Eleni Papadopoulou (NIPH) and Dr Masresha Tessema (EPHI) as they embark on this vital mission.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This